About the ReSPECT™ Clinical Trials
Plus Therapeutics is a U.S. pharmaceutical company developing innovative, targeted radiotherapeutics for adult & pediatric patients with rare & difficult-to-treat cancers. In the ongoing and planned ReSPECT™ Clinical Trials, the safety & effectiveness of an investigational therapy, REYOBIQ™ (rhenium Re186 obisbemeda), will be evaluated in patients with central nervous system (CNS) tumors such as recurrent glioblastoma and leptomeningeal metastases.
What is REYOBIQ™?
REYOBIQ™ is an innovative, targeted radiotherapeutic for central nervous system (CNS) tumors.
It is designed and intended to deliver a high, precise dose of radiation directly to specific cancer cells while sparing normal, healthy cells.
Where to Go for More Information?
Your healthcare provider will assess your eligibility for participation in a ReSPECT™ Clinical Trial. To learn more, explore our clinical trial pages or patient cancer guide sections linked above.